Trial Profile
An open label, single sequence, repeat dose study to investigate the effects of GSK 189075 [remogliflozin etabonate] on the pharmacokinetics of an oral contraceptive pill [ethinylestradiol/norethisterone] when coadministered to healthy female volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Remogliflozin etabonate (Primary) ; Ethinylestradiol/norethisterone
- Indications Pregnancy
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 03 Feb 2010 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 03 Feb 2010 Actual patient number (22) added as reported by ClinicalTrials.gov.
- 12 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.